Evidence map›Paper›PMID 31207189›Full record

ArticleJournal of cachexia, sarcopenia and muscle2019

The prognostic significance of weight loss in chronic obstructive pulmonary disease-related cachexia: a prospective cohort study.

Hoi Yee Kwan, Matthew Maddocks, Claire M Nolan, Sarah E Jones, Suhani Patel, Ruth E Barker, Samantha S C Kon, Michael I Polkey, Paul Cullinan, William D-C Man

Registry-linked trialOpen access · goldAbstract readMulticenter Study
In one paragraph

Article in Journal of cachexia, sarcopenia and muscle, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06344000 (A Study of the Association Between Progression and Nutritional Status in Bronchiectasis), which is not on this map. Cited by 41 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 2 pooled it
5.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06344000 recruitingnot on this mapstarted 2024, after this paper: background citation

A Study of the Association Between Progression and Nutritional Status in Bronchiectasis

TypeobservationalSponsorUnion Hospital, Tongji Medical College, Huazhong University of Science and TechnologyRan2024 to 2027Enrolled300ConditionsBronchiectasisArmsinapplicable
3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 2 syntheses or guidelines pooled it, 75 citations in OpenAlex.

  1. The impact of body mass index on mortality in COPD: an updated dose-response meta-analysis.European respiratory review : an official journal of the European Respiratory Society · 2024
    Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Article
  6. Article
  7. Observational
  8. Medical nutrition therapy in chronic obstructive pulmonary disease: A narrative review.Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition · 2025
    Review
  9. Article
  10. Article
  11. Weight change across adulthood in relation to the risk of COPD.Environmental health and preventive medicine · 2025
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Observational
  20. Deaccelerated Myogenesis and Autophagy in Genetically Induced Pulmonary Emphysema.American journal of respiratory cell and molecular biology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Hoi Yee KwanDepartment of Respiratory Medicine, Kowloon Hospital, HKSAR, China.
Matthew MaddocksCicely Saunders Institute of Palliative Care, Policy and Rehabilitation, King's College London, London, UK.ORCID 0000-0002-0189-0952
Claire M NolanHarefield Pulmonary Rehabilitation and Muscle Research Laboratory, Royal Brompton and Harefield NHS Foundation Trust, London, UK.
Sarah E JonesHarefield Pulmonary Rehabilitation and Muscle Research Laboratory, Royal Brompton and Harefield NHS Foundation Trust, London, UK.
Suhani PatelHarefield Pulmonary Rehabilitation and Muscle Research Laboratory, Royal Brompton and Harefield NHS Foundation Trust, London, UK.
Ruth E BarkerHarefield Pulmonary Rehabilitation and Muscle Research Laboratory, Royal Brompton and Harefield NHS Foundation Trust, London, UK.
Samantha S C KonHarefield Pulmonary Rehabilitation and Muscle Research Laboratory, Royal Brompton and Harefield NHS Foundation Trust, London, UK.
Michael I PolkeyNational Heart and Lung Institute, Imperial College, London, UK.
Paul CullinanNational Heart and Lung Institute, Imperial College, London, UK.
William D-C ManHarefield Pulmonary Rehabilitation and Muscle Research Laboratory, Royal Brompton and Harefield NHS Foundation Trust, London, UK.
Royal Brompton & Harefield NHS Foundation Trust · GBImperial College London · GBHillingdon Hospitals NHS Foundation Trust · GBKing's College London · GB

Funding

Department of Health CDF-2017-10-009Department of Health PB-PG-0213-30003Medical Research Council G1002113
6 · The paper itself

Abstract

backgroundCachexia is an important extra-pulmonary manifestation of chronic obstructive pulmonary disease (COPD) presenting as unintentional weight loss and altered body composition. Previous studies have focused on the relative importance of body composition compared with body mass rather than the relative importance of dynamic compared with static measures. We aimed to determine the prevalence of cachexia and pre-cachexia phenotypes in COPD and examine the associations between cachexia and its component features with all-cause mortality.

methodsWe enrolled 1755 consecutive outpatients with stable COPD from two London centres between 2012 and 2017, stratified according to European Respiratory Society Task Force defined cachexia [unintentional weight loss >5% and low fat-free mass index (FFMI)], pre-cachexia (weight loss >5% but preserved FFMI), or no cachexia. The primary outcome was all-cause mortality. We calculated hazard ratios (HRs) using Cox proportional hazards regression for cachexia classifications (cachexia, pre-cachexia, and no cachexia) and component features (weight loss and FFMI) and mortality, adjusting for age, sex, body mass index, and disease-specific prognostic markers.

resultsThe prevalence of cachexia was 4.6% [95% confidence interval (CI): 3.6-5.6] and pre-cachexia 1.6% (95% CI: 1.0-2.2). Prevalence was similar across sexes but increased with worsening Global Initiative for Chronic Obstructive Pulmonary Disease spirometric stage and Medical Research Council dyspnoea score (all P < 0.001). There were 313 (17.8%) deaths over a median (interquartile range) follow-up duration 1089 (547-1704) days. Both cachexia [HR 1.98 (95% CI: 1.31-2.99), P = 0.002] and pre-cachexia [HR 2.79 (95% CI: 1.48-5.29), P = 0.001] were associated with increased mortality. In multivariable analysis, the unintentional weight loss feature of cachexia was independently associated with mortality [HR 2.16 (95% CI: 1.31-3.08), P < 0.001], whereas low FFMI was not [HR 0.88 (95% CI: 0.64-1.20), P = 0.402]. Sensitivity analyses using body mass index-specific, age-specific, and gender-specific low FFMI values found consistent findings.

conclusionsDespite the low prevalence of cachexia and pre-cachexia, both confer increased mortality risk in COPD, driven by the unintentional weight loss component. Our data suggest that low FFMI without concurrent weight loss may not confer the poor prognosis as previously reported for this group. Weight loss should be regularly monitored in practice and may represent an important target in COPD management. We propose the incorporation of weight monitoring into national and international COPD guidance.

Indexed as

AgedBody Mass IndexCachexiaFemaleHumansLondonMaleMiddle AgedPrevalencePrognosisProspective StudiesPulmonary Disease, Chronic ObstructiveRegression AnalysisSeverity of Illness IndexSurvival AnalysisWeight LossBody compositionCachexiaCOPDMortalityPhenotypes

Identifiers

PMID31207189
PMCPMC6903442
OpenAlexW2952358400

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.